Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer

Exclusion Criteria

• •Peripheral sensory or motor neuropathy \> grade 1
• •Eastern Cooperative Oncology Group (ECOG) Performance status \> 2
• •Serious cardiac arrhythmia, diabetes, or serious active infection or other active illness that would preclude study participation in the opinion of the investigator
• •Pernicious anemia or other megaloblastic anemia with vitamin B12 deficiency
• •Previous (greater than 5 years) or current malignancies of other origin within the past 5 years
• •Lack of physical integrity of the upper gastrointestinal tract, clinically significant malabsorption syndrome, or inability to take oral medications
• •History of known allergy to oxaliplatin or other platinum compounds, to 5-FU, to LV or to any ingredients in the formulations or the containers
• •Severe renal impairment (ClCr \< 50 mL/min)
• •Pregnant women or breast-feeding
• •Patients (male or female) with reproductive potential not implementing accepted and effective method of contraception (the definition of "effective method of contraception" will be based on the investigators' judgment)
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.